查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1871986

口服蛋白質和胜肽：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Oral Proteins and Peptides - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 87 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球口服蛋白質和胜肽市場規模估計為 23.46 億美元，預計到 2031 年將達到 63.55 億美元，在預測期（2025-2031 年）內以 15.3% 的複合年成長率成長。

本報告對口服蛋白質和胜肽領域近期的關稅調整和國際戰略反制措施進行了全面評估，重點關注跨境產業基地、資本配置模式、區域經濟相互依存關係和供應鏈重組。

多肽和蛋白質藥物是指由多肽和蛋白質物質製成的生物製劑，用於預防、治療和診斷。多肽是由α-胺基酸連接成胜肽鏈的化合物，也是蛋白質分解的中間產物。蛋白質是由多條多肽鏈以特定的空間結構相互纏繞而成。多肽是透過水解高分子量蛋白質產生的。這些藥物屬於生化製劑，對其儲存和運輸環境有較嚴格的要求。

隨著給藥技術的進步，口服替代注射已成為新的趨勢，提高了患者的依從性，促進了市場成長。

治療糖尿病和發炎性腸道疾病等慢性疾病的口服蛋白質和胜肽類藥物的需求持續成長。

奈米遞送系統和酵素抑制封裝技術不斷成熟，解決了消化分解問題，並擴大了產品開發的範圍。

世界各地的許多生物製藥公司正在推動臨床試驗和合作開發，以加速商業化進程。

儘管面臨監管挑戰和成本壓力，口服蛋白質和胜肽市場仍然被認為是一個具有巨大潛力的藍海產業。

本報告旨在按地區/國家、類型和應用對全球口服蛋白質和胜肽市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

本報告以2024年為基準年，對口服蛋白質和胜肽的市場規模、估計值和預測進行了闡述，並以銷售量（公斤）和收入（百萬美元）為單位，涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定口服蛋白質和胜肽的業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Ironwood & Allergan（AbbVie）
  • Novo Nordisk
  • Synergy Pharmaceuticals（Salix）
  • Novartis
  • Chiasma（Amryt Pharma）

按類型分類的細分市場

  • 利那洛肽
  • 胰島素
  • Plecanatide
  • Cyclosporine
  • Octreotide

應用領域

  • 胃/消化系統疾病
  • 骨骼疾病
  • 糖尿病
  • 荷爾蒙失調

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Oral Proteins and Peptides was estimated to be worth US$ 2346 million in 2024 and is forecast to a readjusted size of US$ 6355 million by 2031 with a CAGR of 15.3% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Oral Proteins and Peptides cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Polypeptide and protein drugs refer to the biological drugs of polypeptide and protein substances used for prevention, treatment and diagnosis. Polypeptide is a compound formed by linking a-amino acids together with a peptide chain, and it is also an intermediate product of proteolysis. N polypeptide chains are entangled in a certain spatial structure to form a protein. The hydrolysis of macromolecular proteins produces polypeptides. Such drugs are biochemical preparations and have relatively strict requirements on storage and transportation environment.

With the breakthrough of delivery technology, oral alternatives to injections have become a new trend, improving patient compliance and driving market growth.

The demand for oral protein and peptide drugs for the treatment of chronic diseases (such as diabetes and inflammatory bowel disease) continues to rise.

Nano-delivery systems and enzyme inhibition encapsulation technologies continue to mature, solving gastrointestinal degradation problems and expanding product development space.

Many biopharmaceutical companies around the world are advancing clinical trials and cooperative development to accelerate the commercialization process.

Despite regulatory challenges and cost pressures, the oral protein/peptide market is still seen as a high-potential blue ocean track.

This report aims to provide a comprehensive presentation of the global market for Oral Proteins and Peptides, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Oral Proteins and Peptides by region & country, by Type, and by Application.

The Oral Proteins and Peptides market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Proteins and Peptides.

Market Segmentation

By Company

  • Ironwood & Allergan (AbbVie)
  • Novo Nordisk
  • Synergy Pharmaceuticals (Salix)
  • Novartis
  • Chiasma (Amryt Pharma)

Segment by Type

  • Linaclotide
  • Insulin
  • Plecanatide
  • Cyclosporine
  • Octreotide

Segment by Application

  • Gastric & Digestive Disorders
  • Bone Diseases
  • Diabetes
  • Hormonal Disorders

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oral Proteins and Peptides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Oral Proteins and Peptides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Oral Proteins and Peptides in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Oral Proteins and Peptides Product Introduction
  • 1.2 Global Oral Proteins and Peptides Market Size Forecast
    • 1.2.1 Global Oral Proteins and Peptides Sales Value (2020-2031)
    • 1.2.2 Global Oral Proteins and Peptides Sales Volume (2020-2031)
    • 1.2.3 Global Oral Proteins and Peptides Sales Price (2020-2031)
  • 1.3 Oral Proteins and Peptides Market Trends & Drivers
    • 1.3.1 Oral Proteins and Peptides Industry Trends
    • 1.3.2 Oral Proteins and Peptides Market Drivers & Opportunity
    • 1.3.3 Oral Proteins and Peptides Market Challenges
    • 1.3.4 Oral Proteins and Peptides Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Oral Proteins and Peptides Players Revenue Ranking (2024)
  • 2.2 Global Oral Proteins and Peptides Revenue by Company (2020-2025)
  • 2.3 Global Oral Proteins and Peptides Players Sales Volume Ranking (2024)
  • 2.4 Global Oral Proteins and Peptides Sales Volume by Company Players (2020-2025)
  • 2.5 Global Oral Proteins and Peptides Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Oral Proteins and Peptides Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Oral Proteins and Peptides Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Oral Proteins and Peptides
  • 2.9 Oral Proteins and Peptides Market Competitive Analysis
    • 2.9.1 Oral Proteins and Peptides Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Oral Proteins and Peptides Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Proteins and Peptides as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Linaclotide
    • 3.1.2 Insulin
    • 3.1.3 Plecanatide
    • 3.1.4 Cyclosporine
    • 3.1.5 Octreotide
  • 3.2 Global Oral Proteins and Peptides Sales Value by Type
    • 3.2.1 Global Oral Proteins and Peptides Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Oral Proteins and Peptides Sales Value, by Type (2020-2031)
    • 3.2.3 Global Oral Proteins and Peptides Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Oral Proteins and Peptides Sales Volume by Type
    • 3.3.1 Global Oral Proteins and Peptides Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Oral Proteins and Peptides Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Oral Proteins and Peptides Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Oral Proteins and Peptides Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Gastric & Digestive Disorders
    • 4.1.2 Bone Diseases
    • 4.1.3 Diabetes
    • 4.1.4 Hormonal Disorders
  • 4.2 Global Oral Proteins and Peptides Sales Value by Application
    • 4.2.1 Global Oral Proteins and Peptides Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Oral Proteins and Peptides Sales Value, by Application (2020-2031)
    • 4.2.3 Global Oral Proteins and Peptides Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Oral Proteins and Peptides Sales Volume by Application
    • 4.3.1 Global Oral Proteins and Peptides Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Oral Proteins and Peptides Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Oral Proteins and Peptides Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Oral Proteins and Peptides Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Oral Proteins and Peptides Sales Value by Region
    • 5.1.1 Global Oral Proteins and Peptides Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Oral Proteins and Peptides Sales Value by Region (2020-2025)
    • 5.1.3 Global Oral Proteins and Peptides Sales Value by Region (2026-2031)
    • 5.1.4 Global Oral Proteins and Peptides Sales Value by Region (%), (2020-2031)
  • 5.2 Global Oral Proteins and Peptides Sales Volume by Region
    • 5.2.1 Global Oral Proteins and Peptides Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Oral Proteins and Peptides Sales Volume by Region (2020-2025)
    • 5.2.3 Global Oral Proteins and Peptides Sales Volume by Region (2026-2031)
    • 5.2.4 Global Oral Proteins and Peptides Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Oral Proteins and Peptides Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.4.2 North America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.5.2 Europe Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Oral Proteins and Peptides Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.7.2 South America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Oral Proteins and Peptides Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Oral Proteins and Peptides Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Oral Proteins and Peptides Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.3.2 United States Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.4.2 Europe Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.5.2 China Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.6.2 Japan Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.7.2 South Korea Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.9.2 India Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Ironwood & Allergan (AbbVie)
    • 7.1.1 Ironwood & Allergan (AbbVie) Company Information
    • 7.1.2 Ironwood & Allergan (AbbVie) Introduction and Business Overview
    • 7.1.3 Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Product Offerings
    • 7.1.5 Ironwood & Allergan (AbbVie) Recent Development
  • 7.2 Novo Nordisk
    • 7.2.1 Novo Nordisk Company Information
    • 7.2.2 Novo Nordisk Introduction and Business Overview
    • 7.2.3 Novo Nordisk Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Novo Nordisk Oral Proteins and Peptides Product Offerings
    • 7.2.5 Novo Nordisk Recent Development
  • 7.3 Synergy Pharmaceuticals (Salix)
    • 7.3.1 Synergy Pharmaceuticals (Salix) Company Information
    • 7.3.2 Synergy Pharmaceuticals (Salix) Introduction and Business Overview
    • 7.3.3 Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Product Offerings
    • 7.3.5 Synergy Pharmaceuticals (Salix) Recent Development
  • 7.4 Novartis
    • 7.4.1 Novartis Company Information
    • 7.4.2 Novartis Introduction and Business Overview
    • 7.4.3 Novartis Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Novartis Oral Proteins and Peptides Product Offerings
    • 7.4.5 Novartis Recent Development
  • 7.5 Chiasma (Amryt Pharma)
    • 7.5.1 Chiasma (Amryt Pharma) Company Information
    • 7.5.2 Chiasma (Amryt Pharma) Introduction and Business Overview
    • 7.5.3 Chiasma (Amryt Pharma) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Chiasma (Amryt Pharma) Oral Proteins and Peptides Product Offerings
    • 7.5.5 Chiasma (Amryt Pharma) Recent Development

8 Industry Chain Analysis

  • 8.1 Oral Proteins and Peptides Industrial Chain
  • 8.2 Oral Proteins and Peptides Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Oral Proteins and Peptides Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Oral Proteins and Peptides Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Oral Proteins and Peptides Market Trends
  • Table 2. Oral Proteins and Peptides Market Drivers & Opportunity
  • Table 3. Oral Proteins and Peptides Market Challenges
  • Table 4. Oral Proteins and Peptides Market Restraints
  • Table 5. Global Oral Proteins and Peptides Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Oral Proteins and Peptides Revenue Market Share by Company (2020-2025)
  • Table 7. Global Oral Proteins and Peptides Sales Volume by Company (2020-2025) & (Kg)
  • Table 8. Global Oral Proteins and Peptides Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Oral Proteins and Peptides Price by Company (2020-2025) & (US$/kg)
  • Table 10. Key Manufacturers Oral Proteins and Peptides Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Oral Proteins and Peptides Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Oral Proteins and Peptides
  • Table 13. Global Oral Proteins and Peptides Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Proteins and Peptides as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Oral Proteins and Peptides Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Oral Proteins and Peptides Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Oral Proteins and Peptides Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Oral Proteins and Peptides Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Oral Proteins and Peptides Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Oral Proteins and Peptides Sales Volume by Type: 2020 VS 2024 VS 2031 (Kg)
  • Table 22. Global Oral Proteins and Peptides Sales Volume by Type (2020-2025) & (Kg)
  • Table 23. Global Oral Proteins and Peptides Sales Volume by Type (2026-2031) & (Kg)
  • Table 24. Global Oral Proteins and Peptides Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Oral Proteins and Peptides Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Oral Proteins and Peptides Price by Type (2020-2025) & (US$/kg)
  • Table 27. Global Oral Proteins and Peptides Price by Type (2026-2031) & (US$/kg)
  • Table 28. Global Oral Proteins and Peptides Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Oral Proteins and Peptides Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Oral Proteins and Peptides Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Oral Proteins and Peptides Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Oral Proteins and Peptides Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Oral Proteins and Peptides Sales Volume by Application: 2020 VS 2024 VS 2031 (Kg)
  • Table 34. Global Oral Proteins and Peptides Sales Volume by Application (2020-2025) & (Kg)
  • Table 35. Global Oral Proteins and Peptides Sales Volume by Application (2026-2031) & (Kg)
  • Table 36. Global Oral Proteins and Peptides Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Oral Proteins and Peptides Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Oral Proteins and Peptides Price by Application (2020-2025) & (US$/kg)
  • Table 39. Global Oral Proteins and Peptides Price by Application (2026-2031) & (US$/kg)
  • Table 40. Global Oral Proteins and Peptides Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Oral Proteins and Peptides Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Oral Proteins and Peptides Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Oral Proteins and Peptides Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Oral Proteins and Peptides Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Oral Proteins and Peptides Sales Volume by Region (Kg): 2020 VS 2024 VS 2031
  • Table 46. Global Oral Proteins and Peptides Sales Volume by Region (2020-2025) & (Kg)
  • Table 47. Global Oral Proteins and Peptides Sales Volume by Region (2026-2031) & (Kg)
  • Table 48. Global Oral Proteins and Peptides Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Oral Proteins and Peptides Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Oral Proteins and Peptides Average Price by Region (2020-2025) & (US$/kg)
  • Table 51. Global Oral Proteins and Peptides Average Price by Region (2026-2031) & (US$/kg)
  • Table 52. Key Countries/Regions Oral Proteins and Peptides Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Oral Proteins and Peptides Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Oral Proteins and Peptides Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Oral Proteins and Peptides Sales Volume, (2020-2025) & (Kg)
  • Table 56. Key Countries/Regions Oral Proteins and Peptides Sales Volume, (2026-2031) & (Kg)
  • Table 57. Ironwood & Allergan (AbbVie) Company Information
  • Table 58. Ironwood & Allergan (AbbVie) Introduction and Business Overview
  • Table 59. Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 60. Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Product Offerings
  • Table 61. Ironwood & Allergan (AbbVie) Recent Development
  • Table 62. Novo Nordisk Company Information
  • Table 63. Novo Nordisk Introduction and Business Overview
  • Table 64. Novo Nordisk Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 65. Novo Nordisk Oral Proteins and Peptides Product Offerings
  • Table 66. Novo Nordisk Recent Development
  • Table 67. Synergy Pharmaceuticals (Salix) Company Information
  • Table 68. Synergy Pharmaceuticals (Salix) Introduction and Business Overview
  • Table 69. Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 70. Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Product Offerings
  • Table 71. Synergy Pharmaceuticals (Salix) Recent Development
  • Table 72. Novartis Company Information
  • Table 73. Novartis Introduction and Business Overview
  • Table 74. Novartis Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 75. Novartis Oral Proteins and Peptides Product Offerings
  • Table 76. Novartis Recent Development
  • Table 77. Chiasma (Amryt Pharma) Company Information
  • Table 78. Chiasma (Amryt Pharma) Introduction and Business Overview
  • Table 79. Chiasma (Amryt Pharma) Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 80. Chiasma (Amryt Pharma) Oral Proteins and Peptides Product Offerings
  • Table 81. Chiasma (Amryt Pharma) Recent Development
  • Table 82. Key Raw Materials Lists
  • Table 83. Raw Materials Key Suppliers Lists
  • Table 84. Oral Proteins and Peptides Downstream Customers
  • Table 85. Oral Proteins and Peptides Distributors List
  • Table 86. Research Programs/Design for This Report
  • Table 87. Key Data Information from Secondary Sources
  • Table 88. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Oral Proteins and Peptides Product Picture
  • Figure 2. Global Oral Proteins and Peptides Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Oral Proteins and Peptides Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Oral Proteins and Peptides Sales Volume (2020-2031) & (Kg)
  • Figure 5. Global Oral Proteins and Peptides Sales Price (2020-2031) & (US$/kg)
  • Figure 6. Oral Proteins and Peptides Report Years Considered
  • Figure 7. Global Oral Proteins and Peptides Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Oral Proteins and Peptides Players Sales Volume Ranking (2024) & (Kg)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Oral Proteins and Peptides Revenue in 2024
  • Figure 10. Oral Proteins and Peptides Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Linaclotide Picture
  • Figure 12. Insulin Picture
  • Figure 13. Plecanatide Picture
  • Figure 14. Cyclosporine Picture
  • Figure 15. Octreotide Picture
  • Figure 16. Global Oral Proteins and Peptides Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Oral Proteins and Peptides Sales Value Market Share by Type, 2024 & 2031
  • Figure 18. Global Oral Proteins and Peptides Sales Volume by Type (2020 VS 2024 VS 2031) & (Kg)
  • Figure 19. Global Oral Proteins and Peptides Sales Volume Market Share by Type, 2024 & 2031
  • Figure 20. Global Oral Proteins and Peptides Price by Type (2020-2031) & (US$/kg)
  • Figure 21. Product Picture of Gastric & Digestive Disorders
  • Figure 22. Product Picture of Bone Diseases
  • Figure 23. Product Picture of Diabetes
  • Figure 24. Product Picture of Hormonal Disorders
  • Figure 25. Global Oral Proteins and Peptides Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 26. Global Oral Proteins and Peptides Sales Value Market Share by Application, 2024 & 2031
  • Figure 27. Global Oral Proteins and Peptides Sales Volume by Application (2020 VS 2024 VS 2031) & (Kg)
  • Figure 28. Global Oral Proteins and Peptides Sales Volume Market Share by Application, 2024 & 2031
  • Figure 29. Global Oral Proteins and Peptides Price by Application (2020-2031) & (US$/kg)
  • Figure 30. North America Oral Proteins and Peptides Sales Value (2020-2031) & (US$ Million)
  • Figure 31. North America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • Figure 32. Europe Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Asia Pacific Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Asia Pacific Oral Proteins and Peptides Sales Value by Region (%), 2024 VS 2031
  • Figure 36. South America Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. South America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • Figure 38. Middle East & Africa Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Middle East & Africa Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • Figure 40. Key Countries/Regions Oral Proteins and Peptides Sales Value (%), (2020-2031)
  • Figure 41. Key Countries/Regions Oral Proteins and Peptides Sales Volume (%), (2020-2031)
  • Figure 42. United States Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. United States Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 44. United States Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Europe Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Europe Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Europe Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 48. China Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. China Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 50. China Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Japan Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. Japan Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 53. Japan Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 54. South Korea Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. South Korea Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 56. South Korea Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 57. Southeast Asia Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. Southeast Asia Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 59. Southeast Asia Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 60. India Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 61. India Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 62. India Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 63. Oral Proteins and Peptides Industrial Chain
  • Figure 64. Oral Proteins and Peptides Manufacturing Cost Structure
  • Figure 65. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 66. Bottom-up and Top-down Approaches for This Report
  • Figure 67. Data Triangulation
  • Figure 68. Key Executives Interviewed